search

Perspective Therapeutics Inc. (CATX)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results
Nov 10, 2026

Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results

Perspective Therapeutics Inc (NYSE: CATX) reported a narrower Q3 loss of 27 cents per share compared to 35 cents a year ago, though sales significantly dropped to $20,000 from $209,000. Despite encouraging clinical findings, analysts from Piper Sandler and Wedbush lowered their price targets for the stock, which subsequently fell 2.4% to $0.84.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish